201 related articles for article (PubMed ID: 9366556)
1. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.
Mayer U; Wagenaar E; Dorobek B; Beijnen JH; Borst P; Schinkel AH
J Clin Invest; 1997 Nov; 100(10):2430-6. PubMed ID: 9366556
[TBL] [Abstract][Full Text] [Related]
2. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
Smit JW; Huisman MT; van Tellingen O; Wiltshire HR; Schinkel AH
J Clin Invest; 1999 Nov; 104(10):1441-7. PubMed ID: 10562306
[TBL] [Abstract][Full Text] [Related]
3. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
[TBL] [Abstract][Full Text] [Related]
4. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum.
Smith AJ; Mayer U; Schinkel AH; Borst P
J Natl Cancer Inst; 1998 Aug; 90(15):1161-6. PubMed ID: 9701366
[TBL] [Abstract][Full Text] [Related]
5. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
Schinkel AH; Wagenaar E; van Deemter L; Mol CA; Borst P
J Clin Invest; 1995 Oct; 96(4):1698-705. PubMed ID: 7560060
[TBL] [Abstract][Full Text] [Related]
6. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.
Mayer U; Wagenaar E; Beijnen JH; Smit JW; Meijer DK; van Asperen J; Borst P; Schinkel AH
Br J Pharmacol; 1996 Nov; 119(5):1038-44. PubMed ID: 8922756
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
8. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
[TBL] [Abstract][Full Text] [Related]
9. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
[TBL] [Abstract][Full Text] [Related]
10. Effect of the Mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice.
Desrayaud S; De Lange EC; Lemaire M; Bruelisauer A; De Boer AG; Breimer DD
J Pharmacol Exp Ther; 1998 May; 285(2):438-43. PubMed ID: 9580581
[TBL] [Abstract][Full Text] [Related]
11. Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport.
Sadiq MW; Uchida Y; Hoshi Y; Tachikawa M; Terasaki T; Hammarlund-Udenaes M
PLoS One; 2015; 10(5):e0118638. PubMed ID: 25932627
[TBL] [Abstract][Full Text] [Related]
12. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
[TBL] [Abstract][Full Text] [Related]
13. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice.
Salama NN; Kelly EJ; Bui T; Ho RJ
J Pharm Sci; 2005 Jun; 94(6):1216-25. PubMed ID: 15858856
[TBL] [Abstract][Full Text] [Related]
14. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
15. Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats.
Nielsen CU; Abdulhussein AA; Colak D; Holm R
Int J Pharm; 2016 Nov; 513(1-2):78-87. PubMed ID: 27601334
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice.
Kawahara M; Sakata A; Miyashita T; Tamai I; Tsuji A
J Pharm Sci; 1999 Dec; 88(12):1281-7. PubMed ID: 10585223
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin.
Goralski KB; Hartmann G; Piquette-Miller M; Renton KW
Br J Pharmacol; 2003 May; 139(1):35-48. PubMed ID: 12746221
[TBL] [Abstract][Full Text] [Related]
18. Acetaminophen inhibits intestinal p-glycoprotein transport activity.
Novak A; Carpini GD; Ruiz ML; Luquita MG; Rubio MC; Mottino AD; Ghanem CI
J Pharm Sci; 2013 Oct; 102(10):3830-7. PubMed ID: 23897240
[TBL] [Abstract][Full Text] [Related]
19. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Chu C; Abbara C; Noël-Hudson MS; Thomas-Bourgneuf L; Gonin P; Farinotti R; Bonhomme-Faivre L
Biochem Pharmacol; 2009 May; 77(10):1629-34. PubMed ID: 19426700
[TBL] [Abstract][Full Text] [Related]
20. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
Schinkel AH; Mayer U; Wagenaar E; Mol CA; van Deemter L; Smit JJ; van der Valk MA; Voordouw AC; Spits H; van Tellingen O; Zijlmans JM; Fibbe WE; Borst P
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4028-33. PubMed ID: 9108099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
